Jan. 27, 2026 — Cytokinetics, Inc. has announced that Myqorzo (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. Myqorzo was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.

Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac screening and the care they can access. Despite heart disease remaining the leading cause of death in the U.S., the study finds that only 28% of Americans who have had a heart ultrasound were offered it as a preventive measure, and just 30% say they have convenient access to advanced heart screening close to home.

Jan. 27, 2026 — Robocath has launched the world’s first FIH (First-In-Human) clinical study evaluating its new robotic system in coronary artery disease. This second-generation robot, developed thanks to the clinical and technological experience Robocath gained with its first robotic platform – which is already deployed in numerous centers worldwide – integrates unprecedented and unrivaled capabilities designed to meet the increasing demands of complex coronary procedures.

Jan. 26, 2026 — AISAP,  a provider of AI point-of-care diagnostics, has published a new clinical study in the peer-reviewed journal Frontiers in Digital Health. The research provides clinical evidence that AISAP’s deep learning model can accurately detect significant valvular disease and ventricular dysfunction using only a single, focused ultrasound view, even when the images are acquired by non-cardiologists using handheld devices.

Jan. 11, 2026 — The Global Refurbished Medical Imaging Equipment Market Size is projected to grow at a CAGR of 15.07% from 2026 to 2032, according to a new report published by Verified Market Research. The report reveals that the market was valued at $12,990.44 million in 2024 and is expected to reach $40,056.03 million by the end of the forecast period.

Market Overview

Jan. 20, 2026 — Abbott has received CE Mark in Europe for the TactiFlex Duo Ablation Catheter, Sensor Enabled to treat patients with atrial fibrillation (AFib). Following the new approval, the first successful commercial cases using TactiFlex Duo in the European Union were completed this week.

Jan. 20, 2026 — Kardium Inc. has announced the publication of the PULSAR clinical trial results in the Journal of the American College of Cardiology (JACC). This study evaluated the Globe Pulsed Field System by Kardium for the treatment of paroxysmal atrial fibrillation (PAF).

Jan. 20, 2026 — Polarean, a commercial-stage medical imaging company advancing functional MRI of the lungs, has expanded its Xenon MRI platform into cardiopulmonary pharma-sponsored drug development through a multi-center U.S. study in PH-ILD.

On Feb. 19, at 7 p.m. eastern time, Cleerly will present a live webinar on “Women's Heart Health: Uncovering Hidden Risks with AI-QCT,” featuring preventative cardiologist Dr. Suzanne Steinbaum. 

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now